- Home
- NNNN vs AI Comparison
NNNN vs AI Comparison
Compare NNNN & AI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NNNN
- AI
- Stock Information
- Founded
- NNNN 2021
- AI 2009
- Country
- NNNN Germany
- AI United States
- Employees
- NNNN N/A
- AI N/A
- Industry
- NNNN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- AI Computer Software: Prepackaged Software
- Sector
- NNNN Health Care
- AI Technology
- Exchange
- NNNN Nasdaq
- AI Nasdaq
- Market Cap
- NNNN 2.2B
- AI 2.4B
- IPO Year
- NNNN 2025
- AI 2020
- Fundamental
- Price
- NNNN $45.65
- AI $16.82
- Analyst Decision
- NNNN
- AI Hold
- Analyst Count
- NNNN 0
- AI 18
- Target Price
- NNNN N/A
- AI $29.81
- AVG Volume (30 Days)
- NNNN 88.1K
- AI 10.9M
- Earning Date
- NNNN 01-01-0001
- AI 09-03-2025
- Dividend Yield
- NNNN N/A
- AI N/A
- EPS Growth
- NNNN N/A
- AI N/A
- EPS
- NNNN 0.06
- AI N/A
- Revenue
- NNNN $8,185,146.00
- AI $389,056,000.00
- Revenue This Year
- NNNN N/A
- AI $13.06
- Revenue Next Year
- NNNN N/A
- AI $15.85
- P/E Ratio
- NNNN $839.78
- AI N/A
- Revenue Growth
- NNNN 21.95
- AI 25.27
- 52 Week Low
- NNNN $5.18
- AI $14.70
- 52 Week High
- NNNN $55.65
- AI $45.08
- Technical
- Relative Strength Index (RSI)
- NNNN N/A
- AI 31.74
- Support Level
- NNNN N/A
- AI $16.78
- Resistance Level
- NNNN N/A
- AI $17.54
- Average True Range (ATR)
- NNNN 0.00
- AI 0.73
- MACD
- NNNN 0.00
- AI 0.13
- Stochastic Oscillator
- NNNN 0.00
- AI 22.92
About NNNN Anbio Biotechnology Class A Ordinary Shares
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.
About AI C3.ai Inc.
C3.ai Inc is an enterprise artificial intelligence company. The company provides software-as-a-service applications that enable customers to rapidly develop, deploy, and operate large-scale Enterprise AI applications across any infrastructure. It provides solutions under three divisions namely, The C3 AI Platform, which is an end-to-end application development and runtime environment for designing, developing, and deploying AI applications: C3 AI Applications, which is a portfolio of pre-built, extensible, industry-specific, and application-specific Enterprise AI applications: and C3 Generative AI, which combines the utility of large language models. Geographically the company derives revenue from North America, Europe, the Middle East and Africa, Asia Pacific, and the Rest of the World.